Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Which well-known and large cap stocks to do the major analysts on Wall Street like for 2016? Here are 10.
Goldman Sachs has seen many top stocks offering great rewards for 2016. The reason may be different for each, but these are what the wealthiest and most sophisticated investors have been told…
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
Here are four stocks that, while expensive at current levels, have fundamentals good enough to continue and even exceed their success in 2015 through next year.
Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better 2016 for this exciting sector?
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72 in earnings per share (EPS) on $5.72 billion in revenue compared to…
Chris Lange Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.
Chris Lange The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).
Chris Lange 
